125 related articles for article (PubMed ID: 9272105)
1. Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration.
Taga M; Minaguchi H
Eur J Endocrinol; 1997 Aug; 137(2):167-71. PubMed ID: 9272105
[TBL] [Abstract][Full Text] [Related]
2. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
3. Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Imai A; Matsunami K; Ichigo S; Takagi H
Gynecol Endocrinol; 2016; 32(3):250-2. PubMed ID: 26503621
[TBL] [Abstract][Full Text] [Related]
4. The effect of gonadotropin-releasing hormone agonist on type I collagen C-telopeptide and N-telopeptide: the predictive value of biochemical markers of bone turnover.
Amama EA; Taga M; Minaguchi H
J Clin Endocrinol Metab; 1998 Feb; 83(2):333-8. PubMed ID: 9467536
[TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of urinary CrossLaps as a sensitive marker of bone metabolism.
Nakayama H; Yano T; Sagara Y; Ando K; Kasai Y; Taketani Y
Endocr J; 1997 Aug; 44(4):479-84. PubMed ID: 9447279
[TBL] [Abstract][Full Text] [Related]
6. The effect of hormone replacement therapy in postmenopausal women on urinary C-telopeptide and N-telopeptide of type I collagen, new markers of bone resorption.
Taga M; Uemura T; Minaguchi H
J Endocrinol Invest; 1998 Mar; 21(3):154-9. PubMed ID: 9591210
[TBL] [Abstract][Full Text] [Related]
7. Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: a short-term model for evaluation of antiresorptive therapy.
Stroup GB; Hoffman SJ; Vasko-Moser JA; Lechowska BA; Jenkins EL; Dare LC; Gowen M
Bone; 2001 May; 28(5):532-7. PubMed ID: 11344053
[TBL] [Abstract][Full Text] [Related]
8. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease.
Garnero P; Gineyts E; Riou JP; Delmas PD
J Clin Endocrinol Metab; 1994 Sep; 79(3):780-5. PubMed ID: 8077361
[TBL] [Abstract][Full Text] [Related]
9. Changes in urinary excretions of C-telopeptide and cross-linked N-telopeptide of type I collagen during pregnancy and puerperium.
Yamaga A; Taga M; Minaguchi H
Endocr J; 1997 Oct; 44(5):733-8. PubMed ID: 9466331
[TBL] [Abstract][Full Text] [Related]
10. New biochemical markers of bone resorption in the study of postmenopausal osteoporosis.
de la Piedra C; Traba ML; Dominguez Cabrera C; Sosa Henríquez M
Clin Chim Acta; 1997 Sep; 265(2):225-34. PubMed ID: 9385464
[TBL] [Abstract][Full Text] [Related]
11. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis.
Garnero P; Delmas PD
Bone; 2003 Jan; 32(1):20-6. PubMed ID: 12584032
[TBL] [Abstract][Full Text] [Related]
12. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
[TBL] [Abstract][Full Text] [Related]
13. Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment.
Borderie D; Cherruau B; Dougados M; Ekindjian OG; Roux C
Calcif Tissue Int; 1998 Jan; 62(1):21-5. PubMed ID: 9405728
[TBL] [Abstract][Full Text] [Related]
14. Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration.
Taga M; Minaguchi H
Acta Obstet Gynecol Scand; 1996 Feb; 75(2):162-5. PubMed ID: 8604604
[TBL] [Abstract][Full Text] [Related]
15. Markers of bone resorption--measurement in serum, plasma or urine?
Huber F; Traber L; Roth HJ; Heckel V; Schmidt-Gayk H
Clin Lab; 2003; 49(5-6):203-7. PubMed ID: 15285175
[TBL] [Abstract][Full Text] [Related]
16. Estriol add-back therapy in the long-acting gonadotropin-releasing hormone agonist treatment of uterine leiomyomata.
Nakayama H; Yano T; Sagara Y; Kikuchi A; Ando K; Wang Y; Watanabe M; Matsumi H; Osuga Y; Momoeda M; Taketani Y
Gynecol Endocrinol; 1999 Dec; 13(6):382-9. PubMed ID: 10685331
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of Doppler ultrasound in predicting the effect of gonadotropin-releasing hormone agonist (GnRHa) on myoma uteri].
Yoshioka N
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Nov; 47(11):1255-60. PubMed ID: 8543851
[TBL] [Abstract][Full Text] [Related]
18. Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy).
Tahara M; Matsuoka T; Yokoi T; Tasaka K; Kurachi H; Murata Y
Fertil Steril; 2000 Apr; 73(4):799-804. PubMed ID: 10731543
[TBL] [Abstract][Full Text] [Related]
19. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability.
Caird LE; West CP; Lumsden MA; Hannan WJ; Gow SM
Hum Reprod; 1997 Mar; 12(3):436-40. PubMed ID: 9130735
[TBL] [Abstract][Full Text] [Related]
20. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.
Peris P; Alvarez L; Monegal A; Guañabens N; Durán M; Pons F; Martínez de Osaba MJ; Echevarría M; Ballesta AM; Muñoz-Gómez J
Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
